Sobi: Alprolix(R) Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
STOCKHOLM, Oct. 25, 2017 -- (Healthcare Sales & Marketing Network) -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the Saudi Food & Drug Authority (SFDA) in the Kingdom of Saudi Arabia has approved Alprolix® (eftrenonacog alfa), for... Biopharmaceuticals, Regulatory Swedish Orphan Biovitrum, Sobi , Alprolix, eftrenonacog alfa, haemophilia B
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Haemophilia | Hemophilia | Marketing | Middle East Health | Pharmaceuticals | Saudi Arabia Health | Sweden Health